靶向白细胞介素-1通路治疗血液系统疾病患者
本文综述白细胞介素-1α(IL-1α)和IL-1β等IL-1家族细胞因子在血液系统恶性肿瘤、化疗诱导的肠黏膜炎和移植物抗宿主病(GVHD)发病中的作用,并结合动物研究提示靶向IL-1通路可显著改善黏膜炎和GVHD,已有首个临床研究在血液系统恶性肿瘤中开展。
要点
- IL-1α和IL-1β是强效炎性细胞因子,参与感染防御,但产生和信号失调可加重组织损伤。
- IL-1家族细胞因子参与稳态及「应急」造血,并涉及多种髓系和淋系血液系统恶性肿瘤的发病。
- 动物研究提示靶向IL-1通路可显著改善肠黏膜炎和GVHD,首个临床研究已在血液系统恶性肿瘤中开展。
核心结论
- IL-1α和IL-1β可能成为预防和治疗癌症及癌症治疗相关并发症的有价值靶点,首个临床研究已在血液系统恶性肿瘤中开展。
研究设计与样本
- 综述,讨论IL-1家族细胞因子在血液系统恶性肿瘤、化疗诱导的肠黏膜炎和GVHD中的作用,并推测在血液病患者中靶向IL-1通路的治疗可能性。
主要发现
- IL-1α和IL-1β是强效炎性细胞因子,激活局部和全身炎症过程,并参与针对感染的保护性免疫应答。
- IL-1家族细胞因子在稳态及「应急」造血中起重要作用,并参与多种髓系和淋系血液系统恶性肿瘤的发病。
- 在肠黏膜炎和GVHD的发病中,这些细胞因子被认为在起始和进展阶段均起关键作用。
- 来自动物研究的见解提示,靶向IL-1通路可显著改善黏膜炎和GVHD。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Interleukin-1α (IL-1α) and IL-1β are potent inflammatory cytokines that activate local and systemic inflammatory processes and are involved in protective immune responses against infections. However, their dysregulated production and signaling can aggravate tissue damage during infection, inflammatory diseases, and chemotherapy-induced intestinal mucositis. Additionally, cytokines of the IL-1 family play an important role in homeostatic as well as "emergency" hematopoiesis and are involved in the pathogenesis of several myeloid and lymphoid hematological malignancies. In the pathogenesis of intestinal mucositis and graft-versus-host disease (GVHD), these cytokines are considered pivotal during the initiation as well as propagation phase, and insights from animal studies suggest that targeting the IL-1 pathway can significantly ameliorate mucositis and GVHD. Moreover, IL-1α and IL-1β might prove to be valuable targets for both prevention and treatment of cancer and cancer therapy-related complications, and the first clinical studies have already been performed in the setting of hematological malignancies. In this review, we will discuss the role of cytokines of the IL-1 family in hematological malignancies, chemotherapy-induced intestinal mucositis, and GVHD, and speculate on possibilities of therapeutically targeting the IL-1 pathway in hematological patients.
引用
- de Mooij CEM, Netea MG, van der Velden WJFM, et al. Targeting the interleukin-1 pathway in patients with hematological disorders. Blood. 2017. PMID: 28483765. doi:10.1182/blood-2016-12-754994
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。